Equity Profile

LGND

Ligand Pharmaceuticals Incorporated

Health CarePharmaceuticals$4.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Ligand Pharmaceuticals Misses on EPS, Stock Down 9.55%

Metric	Actual	Expected	Surprise
EPS	$1.63	$1.84	-11.4%
Revenue	N/A	$59M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Ligand Pharmaceuticals Misses on EPS, Stock Down 9.55%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.63	$1.84	-11.4%
Revenue	N/A	$59M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Ligand Pharmaceuticals reported earnings that missed expectations on EPS, which likely contributed to the stock's significant decline of 9.55%. The lack of revenue data and guidance may have added to investor uncertainty. Overall, the results indicate challenges in meeting market expectations.

Company Snapshot

Ligand Pharmaceuticals Incorporated (LGND) operates in the health care sector, focusing on developing and commercializing technologies that enhance drug discovery and development. With a market cap of $5 billion, the company plays a crucial role in the pharmaceutical industry by providing innovative solutions that can potentially improve patient outcomes and drive growth in the sector.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating revenue.

$1.84

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products and services.

$59M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q4-2025, Ligand Pharmaceuticals reported an impressive EPS of $2.02, significantly surpassing analyst expectations. The stock reacted positively, gaining 2.50% the following day.

Management Promises & Guidance

Continued focus on expanding partnerships and collaborations.
Commitment to enhancing product pipelines and research initiatives.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Ligand's upcoming earnings, expecting solid performance based on historical trends of exceeding EPS estimates. However, there is caution due to the potential for revenue fluctuations.

Bull Case

If Ligand beats EPS expectations again, it could reinforce investor confidence and lead to a significant stock price increase, continuing the trend of positive market reactions.

Bear Case

Conversely, if the company fails to meet revenue expectations, it could raise concerns about growth sustainability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$1.84

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating revenue.

Revenue

$59M

Total revenue gives insight into the company's sales performance and market demand for its products and services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.84?

Given Ligand's strong history of beating EPS estimates, this will be a critical indicator of ongoing profitability and market confidence.

What will the revenue figure be compared to the consensus of $59M?

Revenue performance is crucial for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to leverage its partnerships for revenue growth, especially given recent successes in their product pipeline.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a larger expected move than historical averages, hinting at potential surprises.

Insider buying activity indicates confidence in the company's future performance.

Key Risk

If revenue comes in below $53M, it could undermine confidence in Ligand's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Ligand to continue its streak of earnings surprises against the backdrop of revenue expectations.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.66 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.91%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±6.8% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

42.7%

Calls (500)P/C Ratio: 0.06Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around 3.1%, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss on earnings could lead to a decline, with historical data suggesting a potential drop of around 3.1%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new partnerships or collaborations that could drive future revenue.
2Management's commentary on product pipeline advancements.
3Insights into operational efficiencies and cost management strategies.
4Any changes in guidance for future quarters.
5Responses to market competition and how it may impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

AXSOME THERAPEUTICS

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating revenue.

$1.84

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products and services.

$59M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q4-2025, Ligand Pharmaceuticals reported an impressive EPS of $2.02, significantly surpassing analyst expectations. The stock reacted positively, gaining 2.50% the following day.

Management Promises & Guidance

Continued focus on expanding partnerships and collaborations.
Commitment to enhancing product pipelines and research initiatives.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Bull Case

If Ligand beats EPS expectations again, it could reinforce investor confidence and lead to a significant stock price increase, continuing the trend of positive market reactions.

Bear Case

Conversely, if the company fails to meet revenue expectations, it could raise concerns about growth sustainability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$1.84

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating revenue.

Revenue

$59M

Total revenue gives insight into the company's sales performance and market demand for its products and services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.84?

Given Ligand's strong history of beating EPS estimates, this will be a critical indicator of ongoing profitability and market confidence.

What will the revenue figure be compared to the consensus of $59M?

Revenue performance is crucial for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ligand's ability to leverage its partnerships for revenue growth, especially given recent successes in their product pipeline.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a larger expected move than historical averages, hinting at potential surprises.

Insider buying activity indicates confidence in the company's future performance.

Key Risk

If revenue comes in below $53M, it could undermine confidence in Ligand's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Ligand to continue its streak of earnings surprises against the backdrop of revenue expectations.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.66 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.91%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±6.8% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

42.7%

Calls (500)P/C Ratio: 0.06Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around 3.1%, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A miss on earnings could lead to a decline, with historical data suggesting a potential drop of around 3.1%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new partnerships or collaborations that could drive future revenue.
2Management's commentary on product pipeline advancements.
3Insights into operational efficiencies and cost management strategies.
4Any changes in guidance for future quarters.
5Responses to market competition and how it may impact growth.